Dr. Linde Miles, PhD

Investigating the role of oncogenic dependency in NPM1-mutant  AML

The NPM1 gene is mutated in 20-35% of acute myeloid leukemias (AML). However, it is unclear how mutant NPM1 drives leukemia development and whether the imparted cellular changes are reversible. This proposal aims to define the cellular consequences of mutant NPM1 and whether loss/inhibition of NPM1 affects these atypical changes.

*This grant is supported by the Children’s Oncology Support Fund (COSF)